Carregant...
Adjuvant Trastuzumab: Does Time Really Matter?
Trastuzumab is now the standard of care for metastatic and early breast cancer; however, questions remain regarding the optimal schedule of trastuzumab in the adjuvant setting. This commentary discusses the results from recent clinical trials with regard to the optimal duration of trastuzumab treatm...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3662838/ https://ncbi.nlm.nih.gov/pubmed/23624497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0094 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|